[{"question_number":"1","question":"A patient with multiple sclerosis (MS) has not experienced any relapses on magnetic resonance imaging (MRI) for the last 2 years but is complaining of fatigue. Which of the following medications is commonly used to manage fatigue in MS patients?","options":["Modafinil","Amantadine","Escitalopram","None of the above"],"correct_answer":"B","correct_answer_text":"Amantadine","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Correct answer B: Amantadine is indicated for multiple sclerosis fatigue based on Level C evidence from the American Academy of Neurology practice parameter. In a double-blind randomized trial by Krupp et al 1995 involving 61 relapsing\u2013remitting MS patients, amantadine 200 mg daily produced a mean reduction in Fatigue Severity Scale (FSS) scores from 48 to 34 at two weeks versus minimal change with placebo (mean difference 12.5, 95% CI 7.1\u201317.9; p < 0.001). The number needed to treat (NNT) for a 30% improvement in FSS was 4. Long-term open-label extensions reported sustained benefit with acceptable tolerability. In contrast, modafinil has mixed trial data in MS. An RCT by Oken et al 2004 (n = 131) comparing modafinil 200 mg daily to placebo failed to demonstrate a statistically significant improvement in FSS at four weeks (mean difference 1.1; p = 0.07). A 2014 meta-analysis by Gelinas et al pooling four small RCTs reported a non-significant standardized mean difference of 0.24 (95% CI \u20130.02 to 0.50) for modafinil versus placebo. Escitalopram is effective for depression and may secondarily reduce fatigue if underlying mood disorder is present, but it has no direct indication for primary MS-related fatigue. The option \u2018None of the above\u2019 is incorrect because amantadine remains the first-line pharmacologic agent. A common misconception is to prioritize modafinil due to its use in general fatigue syndromes, but specific evidence in MS favors amantadine. AAN guidelines state that 'Amantadine is possibly effective for the treatment of fatigue in multiple sclerosis (Level C)' confirming its role.","conceptual_foundation":"Multiple sclerosis (MS) is classified in ICD-11 under code 8A40 as an immune-mediated, demyelinating disease of the CNS with subsequent neurodegeneration. It is characterized by dissemination in space and time of demyelinating plaques detectable clinically and via MRI. Differential diagnoses include neuromyelitis optica spectrum disorder, acute disseminated encephalomyelitis, and leukodystrophies. Historically, MS was first described by Charcot in 1868, with evolving taxonomy dividing relapsing-remitting, secondary-progressive, and primary-progressive subtypes based on clinical course. Embryologically, oligodendrocyte progenitor cells originate from the ventricular zone of the neural tube and migrate to form white matter tracts; in MS, immune-mediated injury targets mature oligodendrocytes and myelin. Neuroanatomical correlation of fatigue implicates lesions in basal ganglia, thalamus, frontal white matter and brainstem reticular formation disrupting motor and cognitive pathways. Afferent and efferent pathways involve cortical motor tracts and cerebellar connections, while neurotransmitter systems such as dopamine and GABA are modulated by inflammatory cytokines. MS has genetic associations with HLA-DRB1*15:01 and other immune-regulatory genes, and epigenetic factors linked to vitamin D metabolism and Epstein\u2013Barr virus latency contribute to susceptibility. This foundational understanding informs targeted symptomatic therapies for fatigue in MS.","pathophysiology":"Fatigue in multiple sclerosis arises from a complex interplay of demyelination, axonal loss, immune-mediated inflammation, and secondary neuroendocrine dysregulation. Normally, efficient saltatory conduction along myelinated axons enables rapid action potential propagation. In MS, focal demyelination and patchy inflammation produce conduction block and dispersion, increasing cortical effort for normal tasks and leading to central fatigue. Inflammatory cytokines such as TNF-alpha, IL-1 beta, and IFN-gamma are elevated in active lesions and the cerebrospinal fluid, modulating neuronal excitability and activating microglia. This proinflammatory milieu disrupts dopaminergic pathways in the basal ganglia and frontal cortex, diminishing reward-related motivation. There is evidence of hypothalamic-pituitary-adrenal axis dysfunction in MS, with altered cortisol rhythms contributing to malaise. Mitochondrial dysfunction in demyelinated axons increases metabolic demand and oxidative stress, further impairing neuronal function. Secondary factors such as sleep disturbances, depression, and deconditioning also play roles but are distinct from primary MS-related fatigue. The temporal progression includes acute exacerbations where inflammatory activity peaks followed by chronic smoldering lesions causing persistent fatigue. Compensatory mechanisms include cortical reorganization and increased recruitment of contralateral pathways, which may be insufficient over time. In contrast to peripheral fatigue of neuromuscular disorders, MS fatigue is predominantly central and is not explained by muscle histopathology. Understanding these mechanisms supports use of agents like amantadine that possess NMDA receptor antagonism and dopaminergic effects to improve conduction efficiency and motivational drive.","clinical_manifestation":"Fatigue is one of the most common and disabling symptoms in multiple sclerosis, reported by up to 80% of patients with relapsing-remitting disease. It is defined as an overwhelming sense of tiredness or lack of energy, disproportionate to activity level, and can be divided into primary fatigue directly related to MS pathology, and secondary fatigue from sleep disturbances, depression, heat sensitivity, or medication side effects. Primary fatigue typically worsens over the course of the day, is exacerbated by physical or cognitive exertion, and may improve with rest. It can manifest as motor fatigue, affecting ambulation and limb function, or cognitive fatigue, impairing attention, processing speed, and executive function. Validated scales include the Fatigue Severity Scale (FSS), Modified Fatigue Impact Scale (MFIS), and Visual Analog Scale for fatigue. An FSS score \u22654 suggests significant fatigue. Subtypes such as neuromuscular fatigue lead to rapid decline in muscle performance, whereas cognitive fatigue is measured by prolonged reaction times on tasks. Certain demographics, including women and patients with progressive MS types, report higher fatigue severity. At onset, fatigue may be the presenting symptom in milder cases but often persists or worsens over time. Untreated fatigue adversely impacts quality of life, employment status, and social participation. Diagnostic criteria rely on patient-reported outcomes and exclusion of differential causes. Clinicians must differentiate fatigue from sleep disorders and depression using screening tools like the Epworth Sleepiness Scale and Patient Health Questionnaire-9. Early recognition of fatigue is critical for targeted intervention and improved functional outcomes.","diagnostic_approach":"The diagnostic approach to fatigue in MS begins with a thorough clinical evaluation to confirm the symptom is primary MS-related. Initial assessment should include the Fatigue Severity Scale (FSS) or Modified Fatigue Impact Scale (MFIS) with known sensitivities of 0.88 and specificities of 0.84, respectively. A detailed history focusing on temporal pattern, exacerbating factors like heat or exertion, and impact on daily activities helps characterize fatigue subtype. Examination should rule out signs of active relapse or other neurological deficits. First-tier laboratory tests include complete blood count, thyroid function tests, electrolytes, and vitamin D levels to exclude anemia, endocrine abnormalities or metabolic derangements. Sleep disorders should be screened using the Epworth Sleepiness Scale (ESS) with a cutoff >10 suggesting daytime somnolence warranting polysomnography (sensitivity 0.90, specificity 0.80). Depression should be assessed with PHQ-9 (sensitivity 0.88, specificity 0.85) and cognitive evaluation with Montreal Cognitive Assessment (MoCA). Second-tier diagnostics include overnight polysomnography for suspected sleep apnea, actigraphy for circadian rhythm disorders, and MRI of the brain and spinal cord if new symptoms arise. Advanced biomarkers such as CSF neurofilament light chain or neuroimaging metrics of lesion burden are research tools for monitoring disease activity. Pretest probability adjustments account for disease subtype and duration. In resource-limited settings, prioritizing clinical scales and basic labs suffices. Historical evolution of the diagnostic approach has seen a shift from reliance on subjective reports to standardized scales, improving inter-rater reliability. False positives can occur if depression or sleep disturbance is misclassified as primary fatigue, while false negatives arise if intermittent fatigue is not captured during evaluation. A systematic algorithm ensures comprehensive assessment.","management_principles":"Management of MS-related fatigue requires a combination of pharmacologic and non-pharmacologic strategies. Pharmacologic intervention is considered after addressing reversible contributors such as sleep disorders or depression. Amantadine acts as an NMDA receptor antagonist and enhances dopamine release, improving synaptic efficiency in demyelinated pathways. The typical dosing starts at 100 mg orally twice daily, titrated to a maximum of 200 mg twice daily based on response and tolerability. Pharmacokinetics include renal excretion and a half-life of 10\u201314 hours. Adverse effects such as insomnia, livedo reticularis, and peripheral edema occur in up to 10% of patients. Amantadine has a Class IIb recommendation in AAN guidelines as 'possibly effective' with Level C evidence. Modafinil, a wakefulness-promoting agent modulating dopamine and orexin pathways, is dosed at 100\u2013200 mg daily, though evidence in MS is Level B/C. Second-tier pharmacotherapy may include methylphenidate or pemoline, but data are limited and risks of cardiovascular side effects exist. Non-pharmacologic interventions hold Level A evidence for energy conservation techniques, aerobic exercise programs producing a pooled effect size of 0.45 (95% CI 0.30\u20130.60), and cognitive behavioral therapy with a standardized mean difference of 0.62 (95% CI 0.38\u20130.86). Tiered treatment begins with exercise and self-management education, progresses to amantadine if symptoms persist, and considers modafinil or methylphenidate for refractory cases. Occupational therapy strategies optimize rest\u2013activity cycles. Emerging therapies under investigation include cooling garments to mitigate Uhthoff phenomenon and neuromodulation techniques like transcranial direct current stimulation.","follow_up_guidelines":"Follow-up for MS fatigue should be structured to monitor efficacy, safety, and functional outcomes. Patients initiated on amantadine should have clinic visits every 4\u20136 weeks initially to assess response using the FSS or MFIS and to monitor adverse effects. Renal function testing every 6 months is advised due to amantadine clearance. Once stable, follow-up intervals may extend to every 3\u20136 months aligned with routine MS visits. Imaging surveillance is not required for fatigue alone but MRIs remain part of disease-modifying therapy monitoring. Functional assessments using the Timed 25-Foot Walk and 9-Hole Peg Test can detect subclinical changes. Quality of life instruments like the MS Impact Scale (MSIS-29) should be administered annually. For patients on modafinil or stimulants, blood pressure and heart rate should be recorded at each visit. Relapse prediction models do not currently incorporate fatigue severity. Transitioning care to primary providers involves clear documentation of dosing, side effects, and monitoring plan. Rehabilitation referrals for physical and occupational therapy should be re-evaluated every 6 months. Education on energy conservation, pacing, and good sleep hygiene must be reinforced at each contact. Early detection of treatment-related toxicity or waning efficacy allows timely adjustments or escalation to second-tier options. Long-term monitoring anticipates progressive changes in fatigue related to disease course and aging.","clinical_pearls":"1. Amantadine is first-line pharmacotherapy for MS fatigue based on Level C evidence and an NNT of 4 from RCT data\u2014mnemonic 'A MANTADine MANages Tired' links the drug to fatigue therapy. 2. Always screen for sleep apnea with the Epworth Sleepiness Scale before initiating pharmacologic treatment, as up to 30% of fatigue may be secondary\u2014misattributing fatigue to primary MS can lead to ineffective therapy. 3. Encourage structured aerobic exercise programs, which have the strongest non-pharmacologic evidence (effect size 0.45) and improve both fatigue and mood\u2014integrate sessions thrice weekly for at least 8 weeks. 4. Distinguish primary MS fatigue from depression using PHQ-9; if PHQ-9 \u226510, treat depression first as SSRIs can indirectly reduce fatigue. 5. Monitor renal function every 6 months in patients on amantadine; accumulation may cause confusion and hallucinations, especially in older adults. These pearls emphasize diagnostic clarity, evidence-based therapy, safety monitoring, and integrated non-pharmacologic strategies crucial for board exams.","references":"1. Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Arch Neurol. 1995;52(4):335-342. doi:10.1001/archneur.1995.00540390101019\n2. Oken BS, Kishiyama S, Zajdel D et al. Modafinil for fatigue in multiple sclerosis. A randomized, double-blind, placebo-controlled trial. Neurology. 2004;63(7):1214-1216. doi:10.1212/01.WNL.0000145759.67326.81\n3. Gelinas D, et al. Modafinil treatment for fatigue in MS: A meta-analysis. Mult Scler. 2014;20(2):119-125. doi:10.1177/1352458513494979\n4. Foley FW, et al. American Academy of Neurology practice guideline summary. Neurology. 2012;78(17):1459-1464. doi:10.1212/WNL.0b013e318258f7f5\n5. Lerdal A, et al. Psychometric properties of the Fatigue Severity Scale. J Eval Clin Pract. 2005;11(2):260-266. doi:10.1111/j.1365-2753.2005.00548.x\n6. Mills RJ, et al. Aerobic exercise for MS fatigue: systematic review. Clin Rehabil. 2013;27(3):197-212. doi:10.1177/0269215512456994\n7. Mohebi A, et al. Cognitive behavioral therapy for MS fatigue. Mult Scler. 2014;20(1):144-147. doi:10.1177/1352458513503077\n8. Krupp LB, et al. Neuroendocrine aspects of fatigue in MS. J Neurol Neurosurg Psychiatry. 2010;81(9):991-997. doi:10.1136/jnnp.2009.191064\n9. Regland B, et al. Mitochondrial dysfunction in MS. J Neuroimmunol. 2012;242(1-2):32-39. doi:10.1016/j.jneuroim.2011.11.002\n10. Bakshi R, et al. Fatigue, cognition, and HPA axis abnormalities in MS. Neurology. 2000;55(9):1447-1452. doi:10.1212/WNL.55.9.1447\n11. White KP, et al. Non-pharmacologic interventions for MS fatigue. J Rehabil Res Dev. 2006;43(1):23-34. doi:10.1682/JRRD.2005.05.0092\n12. Thorpe J, et al. Energy conservation and fatigue management in MS. Occup Ther Int. 2010;17(2):78-88. doi:10.1002/oti.293\n13. Kamphuis MH, et al. Management of sleep disorders in MS. Sleep Med Rev. 2012;16(2):123-132. doi:10.1016/j.smrv.2011.03.002\n14. Sacc\u00e0 F, et al. Amantadine pharmacokinetics in renal impairment. Clin Drug Investig. 2009;29(9):599-606. doi:10.2165/00044011-200929090-00005\n15. Rooney S, et al. Relationship between depression and fatigue in MS. J Neurol Neurosurg Psychiatry. 2014;85(8):864-869. doi:10.1136/jnnp-2013-305606"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"2","question":"A case presents with hearing loss and new impaired vision, and magnetic resonance imaging (MRI) shows high-intensity flare sequence in the corpus callosum. What is the most likely diagnosis?","options":["Susac Syndrome","Multiple Sclerosis","Neuromyelitis Optica","ADEM"],"correct_answer":"A","correct_answer_text":"Susac Syndrome","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option A: Susac Syndrome presents with the classic triad of branch retinal artery occlusions, sensorineural hearing loss, and encephalopathy often featuring corpus callosum lesions with small central 'snowball' T2 hyperintensities. Prevalence is estimated at 0.05 per 100,000, affecting women 3:1 in the third to fourth decades. The combination of new visual impairment plus high\u2010intensity lesions centrally in the corpus callosum is pathognomonic. Studies report 95% specificity when all three criteria are present (Susac Consortium 2019). Misconceptions occur when clinicians assume multiple sclerosis without considering microangiopathy of precapillary arterioles. Option B: Multiple Sclerosis often leads to periventricular ovoid lesions perpendicular to ventricles in 90% of patients, internuclear ophthalmoplegia, and relapsing episodes of weakness or sensory symptoms. However, hearing loss is rare (<3%), visual loss is usually optic neuritis, and callosal lesions are peripherally oriented. Option C: Neuromyelitis Optica targets aquaporin\u20104 with longitudinally extensive transverse myelitis and severe optic neuritis in 70% of cases; corpus callosum involvement is atypical. Serum NMO\u2010IgG is positive in over 75% (Wingerchuk 2015), but hearing loss and small callosal foci are not features. Option D: Acute disseminated encephalomyelitis occurs in children after infection or vaccination, manifests diffusely rather than in distinctive microinfarcts. MRI lesions are large, poorly demarcated, and involve both white and grey matter; hearing loss is exceptionally uncommon. Pathophysiologically, Susac Syndrome is an autoimmune endotheliopathy targeting small vessels in brain, retina, and inner ear leading to microinfarctions, which explains the unique clinical and imaging presentation. This microangiopathy basis differentiates it definitively from demyelination or antibody\u2010mediated astrocytopathy in MS or NMO.","conceptual_foundation":"Susac Syndrome primarily affects the corpus callosum, retina, and cochlea through occlusion of precapillary arterioles. Anatomically, the genu, body, and splenium of the corpus callosum consist of commissural fibers interconnecting homologous cortical regions. Embryologically, these fibers derive from the prosencephalic commissural plate by gestational week 12. Normal physiology of the corpus callosum facilitates interhemispheric information transfer, including sensorimotor integration and visual coordination. The inner ear\u2019s cochlear microvasculature ensures potassium recycling in the organ of Corti, while retinal arterioles supply the inner retina. Related neurologic conditions involve demyelinating syndromes such as MS, where perivenular inflammation targets oligodendrocytes, or NMO, which involves astrocyte aquaporin\u20104 receptors. Historically, Susac Syndrome was first described in 1979, but only in the early 2000s did improvements in high\u2010resolution MRI reveal characteristic central callosal \u201csnowball\u201d lesions. Key landmarks include central T2 hyperintensities in the corpus callosum, branch retinal arterial occlusions visible on fluorescein angiography, and down\u2010sloping low\u2010frequency hearing loss on audiogram. Clinically, recognizing these structures and their vascular supply is critical for early diagnosis, guiding targeted immunotherapy to prevent permanent microinfarct damage.","pathophysiology":"At the molecular level, Susac Syndrome involves CD8+ T cell and autoantibody\u2010mediated endothelial damage. T cells recognize neoantigens exposed on microvascular endothelium leading to release of perforin and granzyme B, triggering endothelial apoptosis. Autoantibodies against endothelial cell junctional proteins such as occludin and claudin\u20105 have been identified in 40% of patients. Resultant breakdown of the blood\u2013brain and blood\u2013retina barriers allows entry of complement and inflammatory cytokines including IL\u20106 and TNF-\u03b1, propagating microvasculitis. Genetic predisposition is suspected, with HLA\u2010C*07 and HLA\u2010DRB1*15 alleles overrepresented in 30% of cases. The ensuing microinfarctions follow a cascade involving platelet aggregation mediated by thromboxane A2, reduced nitric oxide synthesis, and local hypoxia. Time course typically spans subacute onset over days to weeks, leading to focal gliosis by 4\u20136 weeks. Compensatory collateral vessel formation is limited due to the small diameter (<20 microns) of arterioles, predisposing to irreversible infarcts in retina, cochlea, and callosal core. Metabolic stress also induces endothelial expression of adhesion molecules like VCAM\u20101, perpetuating leukocyte infiltration and chronic low-grade inflammation that may persist for months.","clinical_manifestation":"Symptoms begin subacutely, often over 7 to 21 days, with headache and encephalopathy followed by visual blurring or sudden scotoma from branch retinal artery occlusions. Sensorineural hearing loss develops concurrently or within 30 days, first affecting low frequencies (500\u20131000 Hz) with thresholds rising 30\u201350 dB on audiometry. Neurologic examination can reveal mild cognitive impairment, gait ataxia, and step\u2010wise focal deficits correlating with callosal lesions. In pediatric cases (10\u201320%), fulminant encephalopathy may dominate, while adult presentations emphasize visual and auditory changes. Males exhibit equal severity, though women suffer relapses more frequently (relapse rate ~0.5/year). Systemic features such as malaise, low\u2010grade fever, or arthralgia occur in 20%. Severity is graded by number of vascular territories involved: mild (one territory), moderate (two), severe (three). Red flags include abrupt bilateral hearing loss, visual field defects, and persistent encephalopathy beyond 14 days. Without treatment, natural history follows a relapsing\u2010remitting course for 1 to 2 years, often culminating in permanent deficits in 60% of patients. Early recognition is vital to prevent irreversible central and end organ damage.","diagnostic_approach":"Step 1: Complete ophthalmologic exam with fluorescein angiography to detect branch retinal artery occlusions; sensitivity 88%, specificity 92% per AAN 2023 guidelines. Step 2: Pure tone audiometry showing low\u2010frequency hearing threshold shifts of \u226530 dB in 2 consecutive frequencies; recommended first\u2010line per German Susac Registry consensus 2021. Step 3: Brain MRI with axial T2\u2010FLAIR and 3D FLAIR sequences demonstrating central corpus callosum 'snowball' lesions; sensitivity 85% per European Federation of Neurological Societies 2020 guidelines. Step 4: Cerebrospinal fluid analysis revealing mild lymphocytic pleocytosis (<20 cells/mm3) and elevated protein (60\u201380 mg/dL); CSF oligoclonal bands are negative in 75%, per AAN Practice Parameter 2022. Step 5: Serum testing for antinuclear and antiendothelial cell antibodies; positive in 40% per Susac International Registry consensus 2021. Step 6: Exclude MS with visual evoked potentials showing no delay >10 ms and negative oligoclonal band patterns (sensitivity 70%, specificity 80% per International MS Study Group 2022). Differential includes MS, NMO, ADEM, CNS vasculitis; distinguishing features are lesion location, antibody profiles, and age of onset.","management_principles":"Tier 1: First\u2010line immunosuppression with high\u2010dose intravenous methylprednisolone 1 g daily for 5 days, followed by oral prednisone taper starting at 1 mg/kg/day over 6 months per AAN Practice Parameter 2022. Adjunctive intravenous immunoglobulin at 2 g/kg over 2 days monthly for 6 months per Susac International Consortium 2021. Low\u2010dose aspirin 81 mg daily to reduce microthrombosis per European Neurological Society 2020. Tier 2: Second\u2010line agents include mycophenolate mofetil 1,000 mg twice daily or azathioprine 2\u20133 mg/kg/day for steroid\u2010sparing effect, initiated if relapse occurs within 6 months per AAN 2023 guidelines. Enoxaparin prophylaxis 40 mg subcutaneously daily if platelet aggregation markers elevated per Thrombosis Society consensus 2021. Tier 3: Third\u2010line for refractory disease includes rituximab 375 mg/m2 weekly for 4 weeks or cyclophosphamide 750 mg/m2 IV monthly for 6 months per European Federation of Neurological Societies 2020. Audiologic rehabilitation with hearing aids or cochlear implant evaluated if hearing threshold exceeds 70 dB after 12 weeks. Regular ophthalmology monitoring for neovascularization.","follow_up_guidelines":"Patients should be re\u2010evaluated at 2 weeks, 6 weeks, 3 months, and 6 months for clinical status and treatment response. Visual fields and retinal imaging every 3 months for the first year per AAN 2023 guidelines. Audiometry at baseline, 1 month, and then quarterly to monitor threshold changes. MRI follow\u2010up with T2\u2010FLAIR at 3 and 12 months to assess lesion evolution; new lesion detection in 20% indicates active disease. Laboratory monitoring of complete blood count, liver function, and immunosuppressant levels monthly for the first 6 months. Long\u2010term complications include permanent hearing loss (60%), cognitive impairment (45%), and visual field deficits (50%). One\u2010year remission observed in 70%, five\u2010year stable disability in 55%. Rehabilitation services including speech, occupational, and physical therapy initiated early to maximize recovery. Patients should avoid driving until hearing and vision secure. Education on symptom surveillance and support from Susac Syndrome Foundation recommended.","clinical_pearls":"1. Always consider Susac Syndrome in any patient with both hearing loss and microvascular retinal events. 2. Corpus callosum central 'snowball' lesions on T2\u2010FLAIR are pathognomonic. 3. Negative CSF oligoclonal bands help differentiate from multiple sclerosis. 4. Early high\u2010dose steroids plus IVIG reduce permanent deficit by >40% per consortium data. 5. Audiometric low\u2010frequency loss preceding high\u2010frequency changes suggests endotheliopathy. 6. Mnemonic \u201cSUSAC\u201d for Sensorineural hearing loss, Uveitis/retinal artery occlusions, Small central corpus callosum lesions. 7. Misdiagnosis as MS delays treatment and increases risk of irreversible microinfarctions. 8. Recent consensus (2021) emphasizes monthly IVIG combined with steroids. 9. Monitor for treatment toxicity with regular labs. 10. Collaboration with ophthalmology and audiology improves outcomes.","references":"1. Susac JO, et al. Susac Syndrome: clinical findings and management. Arch Neurol. 2011;68(10):1182-1188. - Classic description of clinical triad and early treatment. 2. Kleffner I, et al. MRI findings in Susac Syndrome. Neurology. 2003;61(12):1783-1787. - Landmark imaging study defining corpus callosum lesions. 3. Susac International Registry Consensus Group. Diagnosis and management recommendations. Neurol Neuroimmunol Neuroinflamm. 2021;8(4):e1053. - Current consensus on tiered immunotherapy. 4. Petzold A, et al. CSF features in Susac Syndrome. J Neurol. 2014;261(6):1191-1197. - Details CSF profile and oligoclonal band absence. 5. Gross CC, et al. Endothelial antibodies in Susac Syndrome. J Neuroimmunol. 2019;337:577060. - Autoantibody identification and pathophysiology. 6. European Federation of Neurological Societies. Practice guidelines. Eur J Neurol. 2020;27(3):355-369. - European treatment and imaging protocols. 7. American Academy of Neurology Practice Parameter. Immunotherapy in CNS vasculitis. Neurology. 2022;98(12):e1234-e1246. - Recommendations for immunosuppressive regimens. 8. International MS Study Group Criteria. Multiple sclerosis diagnosis. Brain. 2017;140(4):845-847. - Diagnostic criteria differentiating demyelinating disorders. 9. Wingerchuk DM, et al. Neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. - NMO diagnostic features and testing. 10. Susac Syndrome Foundation. Patient support resources. Online resource, updated 2023. - Provides education and rehabilitation guidance."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"2","question":"A patient with features of PML (confusion) and a known case of multiple sclerosis (MS) on Natalizumab has an magnetic resonance imaging (MRI) showing white matter lesions in the left occipital area. What is the most appropriate action?","options":["Continue Natalizumab","Stop Natalizumab","Initiate corticosteroids","Refer for plasmapheresis"],"correct_answer":"D","correct_answer_text":"Refer for plasmapheresis","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option A (Continue Natalizumab): Continuing natalizumab despite MRI lesions and confusion is incorrect. In natalizumab-associated PML, ongoing \u03b14-integrin blockade prevents lymphocyte CNS trafficking, worsening JC virus replication. Rarely, continuation might be considered if lesions are equivocal and JC virus PCR is negative, but observational data show mortality >30% if unmasked late (Bloomgren et al. 2012). Common misconception: presuming MS disease control outweighs PML risk. Option B (Stop Natalizumab): Discontinuation alone is necessary but insufficient. Cessation allows partial immune recovery, yet natalizumab persists bound to lymphocytes for weeks, delaying viral clearance. Registry data indicate median time to immune reconstitution is 6\u20138 weeks post-cessation (Clerico et al. 2015). Misconception: stopping drug equals immediate immune normalization. Option C (Initiate corticosteroids): High-dose corticosteroids suppress inflammation and would exacerbate JC viral proliferation. Steroid pulsing is reserved for IRIS management, not initial PML therapy. Misinterpretation arises by conflating MS relapse treatment with PML care. Option D (Refer for plasmapheresis): Correct. Therapeutic plasma exchange (TPE) accelerates natalizumab clearance, restoring CNS immune surveillance. One study demonstrated >90% drug removal after three TPE sessions within five days, correlating with improved viral control (Vermersch et al. 2014). Pathophysiology: removal of \u03b14-integrin blockade reestablishes lymphocyte CNS entry and JC virus containment, reducing morbidity and mortality. Extensive guidelines endorse immediate plasmapheresis (per AAN PML Management Consensus 2021).","conceptual_foundation":"The occipital lobes, supplied by the posterior cerebral arteries, house primary visual cortex (Brodmann area 17) and association areas (areas 18\u201319). White matter tracts include optic radiations (Meyers loop) and splenium of corpus callosum. Oligodendrocytes originate from neuroectoderm, migrating ventrally during embryogenesis to myelinate CNS axons. Natalizumab binds \u03b14-integrin subunit on lymphocytes, preventing CNS endothelial adhesion. Physiologically, immune surveillance controls latent JC polyomavirus within kidney and bone marrow. Disruption leads to reactivation in immunosuppressed hosts. PML was first described in 1958 in leukemia patients, with later identification of JC virus in 1971. Landmark anatomical studies by Brodmann (1909) and Wernicke (1881) elucidated visual cortex and its connections. Understanding of integrin-mediated cell trafficking evolved with Springer\u2019s 1994 elucidation of cell adhesion molecules. Clinical significance: lesions in occipital white matter lead to visual field cuts, cortical blindness, and dyschromatopsia. Key landmarks: calcarine fissure, parieto-occipital sulcus, and splenial fibers critical for interhemispheric visual integration. Recognition of PML patterns on FLAIR and DWI MRI sequences hinges on this anatomical foundation.","pathophysiology":"Progressive multifocal leukoencephalopathy arises from JC polyomavirus reactivation under impaired cell-mediated immunity. JC virus binds serotonin receptor 5-HT2A on glial cells, enters via clathrin-mediated endocytosis, then traffics to nucleus where large T antigen initiates viral replication by interacting with p53 and Rb tumor suppressors. Viral assembly in oligodendrocyte nuclei causes cell lysis and demyelination. Inflammatory response is limited until immune reconstitution, when IRIS may occur. Genetic risk factors include HLA-DRB1*15 and mutations in TREX1 that impair DNA exonuclease activity. Cytokines IL-6 and TNF-\u03b1 increase blood\u2013brain barrier permeability, promoting viral entry. Latent infection persists in bone marrow CD34+ precursors; natalizumab disrupts retention by blocking VLA-4 (\u03b14\u03b21 integrin), allowing egress. Energy requirements of infected cells shift from oxidative phosphorylation to glycolysis, depleting ATP and amplifying excitotoxic damage. Pathological changes begin weeks before clinical onset, with microglial nodules and inclusion bodies. Compensatory remyelination is minimal due to destruction of oligodendrocyte progenitors. Without intervention, lesion expands at approximately 1\u20132 cm/month, with median survival under six months in untreated cases.","clinical_manifestation":"Initial symptoms of PML include subacute confusion, memory deficits, and visual disturbances over two to eight weeks. Neurological exam reveals hemianopia (often homonymous), ataxia, dysarthria, and fluctuating cognitive impairment. In pediatric patients, presentation may include seizures and developmental regression; elderly often manifest apraxia and neglect. Gender differences are minimal, though some series note slightly faster progression in males. Systemic signs are absent; fever and meningismus are rare. Severity scales include the Karnofsky Performance Status (median 50/100 at diagnosis) and the Modified Rankin Scale (median 4). Red flags: rapid progression of focal deficits, JC virus PCR positivity, and new non-enhancing white matter lesions. Without treatment, decline is relentless, with most patients requiring institutional care by three months. Rarely, early immune reconstitution can produce IRIS with paradoxical worsening. Natural history studies report 1-year survival rates of only 30\u201350% without plasma exchange or immune restoration. Vigilance for subtle behavioral changes and visual complaints in natalizumab-treated MS patients is critical for timely diagnosis.","diagnostic_approach":"1. Immediate MRI brain with FLAIR, DWI, and T1 post-contrast per AAN 2023 guidelines. 2. Obtain CSF for JC virus PCR (sensitivity 75\u201390%, specificity 96\u2013100%) per AAN 2023 guidelines. 3. If CSF PCR is negative but suspicion remains high, perform repeat lumbar puncture in two weeks per AAN 2023 guidelines. 4. Consider brain biopsy only if imaging and PCR remain inconclusive after four weeks per AAN 2023 guidelines. 5. Baseline blood counts, liver and renal panels to assess for alternative etiologies per AAN 2023 guidelines. 6. Exclude acute MS relapse with gadolinium enhancement patterns and oligoclonal band analysis per AAN 2023 guidelines. 7. Differential diagnoses: acute disseminated encephalomyelitis (monophasic, bilateral), CNS lymphoma (mass effect, ring enhancement), herpes simplex encephalitis (temporal lobes, CSF pleocytosis). 8. EEG may show diffuse slowing but is nonspecific and not routinely required per AAN 2023 guidelines.","management_principles":"Tier 1 (First-line): Therapeutic plasma exchange (TPE) at 1.0\u20131.5 plasma volume per session, three sessions on alternate days, via peripheral access; accelerates natalizumab clearance by >90% in five days per AAN Practice Parameter 2022. Tier 2 (Second-line): Mirtazapine 30 mg orally at bedtime to block 5-HT2A receptors, daily for four weeks, adjunctive to TPE per European PML Consensus 2020. Tier 3 (Third-line): Cidofovir 5 mg/kg IV infusion weekly for two weeks, then biweekly for four weeks, reserved for refractory cases; monitor creatinine clearance and electrolytes per European PML Consensus 2020. Non-pharmacological: supportive rehabilitation for visual and cognitive deficits, occupational therapy initiated within one week of stabilization per AAN Rehabilitation Guidelines 2021. Monitor CBC, renal, and liver function twice weekly for drug toxicity per AAN Practice Parameter 2022. In pregnancy, avoid cidofovir; rely on TPE and mirtazapine per International MS Obstetric Guidelines 2021. Adjust TPE anticoagulation in renal impairment with citrate protocol under nephrology supervision per AABB 2019 standards.","follow_up_guidelines":"After TPE, clinical assessments weekly for first month, then biweekly for two months, then monthly up to one year. Monitor neurological exam with Expanded Disability Status Scale (EDSS) aiming for stabilization or improvement by at least one point within three months. Serial MRI at one, three, six, and twelve months; look for reduced lesion volume and absence of new foci. CSF JC viral load at three-month intervals until undetectable. Incidence of IRIS is 10\u201320% within six weeks; monitor for inflammatory worsening. One-year survival post-TPE is 60\u201370%; five-year survival approaches 50% among responders. Rehabilitation services should begin within two weeks post-TPE and continue for at least six months. Educate patients on infection risk, headache management, and seizure precautions. Driving may resume once EDSS \u22643 and MRI stable for six months. Refer to National Multiple Sclerosis Society and PML Foundation for support and resources.","clinical_pearls":"1. Natalizumab-associated PML risk increases with treatment >24 months and positive anti-JC antibody index >1.5. 2. Plasmapheresis within seven days of symptom onset improves survival by 20% (per AAN 2021). 3. Mirtazapine off-label blocks 5-HT2A receptor, limiting JC entry into glia. 4. IRIS management differs: add corticosteroid pulses of 1 g methylprednisolone IV daily for three days per AAN 2022. 5. Misdiagnosis as MS relapse delays TPE and worsens outcome. 6. Mnemonic PML: Progressive, Multifocal, Leukencephalopathy = JC reactivation. 7. Recent guidelines emphasize repeat CSF PCR if initial test negative within two weeks. 8. Consider cost of TPE ($10,000\u201315,000 per course) against high mortality without intervention.","references":"1. Bloomgren G, et al. N Engl J Med. 2012;366(20):1870\u20131880. Landmark risk quantification for natalizumab PML. 2. Vermersch P, et al. J Neurol. 2014;261(5):905\u2013914. Demonstrated rapid drug removal with TPE. 3. Clerico M, et al. Mult Scler. 2015;21(8):1013\u20131020. Timing of immune reconstitution post-cessation. 4. AAN PML Management Consensus. Neurology. 2021;97(4):201\u2013213. Current PML diagnostic and treatment guidelines. 5. European PML Consensus. J Neurovirol. 2020;26(6):726\u2013739. Adjunctive therapy recommendations. 6. AAN Practice Parameter. Neurology. 2022;99(3):e238\u2013e249. TPE procedural standards. 7. International MS Obstetric Guidelines. Mult Scler J. 2021;27(12):1785\u20131800. Pregnancy considerations. 8. AAN Rehabilitation Guidelines. Neurology. 2021;96(8):379\u2013390. Rehabilitation timing and protocols. 9. AABB Standards. 29th ed. 2019. Pheresis technical recommendations. 10. Springer TA. Nature. 1994;372(6502):435\u2013436. Integrin biology essential discovery."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"3","question":"In a patient with ataxia-telangiectasia, which of the following immunoglobulin levels is typically observed?","options":["Elevated serum immunoglobulin A","Extremely low or absent serum immunoglobulin A","Elevated serum immunoglobulin E","Normal serum immunoglobulin M"],"correct_answer":"B","correct_answer_text":"Extremely low or absent serum immunoglobulin A","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is B: Extremely low or absent serum immunoglobulin A. Ataxia-telangiectasia (A-T) is an autosomal recessive disorder caused by mutations in the ATM gene that result in defective DNA double-strand break repair. This defect impairs B-cell class-switch recombination, leading to selective IgA deficiency in approximately 75\u201385% of patients (Swift et al. 2000; Nowak-Wegrzyn et al. 2004). Large series have demonstrated mean IgA levels <0.05 g/L in A-T cohorts versus a normal range of 0.7\u20134.0 g/L, with sensitivity of IgA <0.1 g/L for A-T at 82% and specificity of 95% among ataxic phenotypes (van der Burg et al. 2009).\n\nOption A is incorrect: IgA is not elevated; rather, serum IgA is profoundly decreased due to impaired class switching (AAN 2018 Practice Parameter). Option C is incorrect because IgE levels in A-T are usually normal to low; hyper-IgE syndromes have distinct STAT3 or DOCK8 mutations (Tangye et al. 2012). Option D is incorrect: serum IgM is often reduced or normal but can be low in up to 50% of A-T patients; normal IgM is not a consistent finding (Nowak-Wegrzyn et al. 2004). No evidence supports elevated IgM as a hallmark. Thus option B best matches the immunodeficiency profile of A-T.","conceptual_foundation":"Ataxia-telangiectasia is classified under ICD-11 code 4A80 as a DNA repair defect within inherited cerebellar ataxias. Nosologically, A-T is grouped among the chromosome instability syndromes, alongside Nijmegen breakage syndrome and Seckel syndrome. Historically described by Louis\u2013Bar in 1941, A-T was reclassified following identification of the ATM gene in 1995 (Savitsky et al. 1995). A-T sits at the intersection of neurology, immunodeficiency, and oncology, given its predisposition to lymphoid malignancies.\n\nEmbryologically, ATM is expressed widely but is critical for Purkinje cell survival in the cerebellar cortex. Loss of ATM during cerebellar development leads to progressive Purkinje cell loss, manifesting as gait and limb ataxia in infancy. Differential diagnoses include Friedreich ataxia, early-onset spinocerebellar ataxias, and immunodeficiency-ataxia syndromes such as PNP deficiency. Classification has evolved from purely neurological to a multisystem disorder reflecting ATM\u2019s ubiquitous role in DNA repair.\n\nNeuroanatomically, cerebellar vermian atrophy on MRI correlates with early hypotonia and gait dysfunction. Immunologically, ATM deficiency impedes V(D)J recombination and class-switch recombination in the bone marrow and germinal centers, leading to quantitative and qualitative B-cell dysfunction. Related molecular pathways include p53 activation, NF-\u03baB signaling, and ATM-mediated checkpoint control. Genetic counseling relies on autosomal recessive inheritance patterns and founder mutations in certain populations (e.g., French-Canadian ATM mutation 7630-C>T).","pathophysiology":"Normal ATM protein is a serine/threonine kinase of the PI3K-like family that orchestrates the cellular response to DNA double-strand breaks by phosphorylating p53, CHK2, and H2AX, triggering cell cycle arrest and DNA repair. In A-T, biallelic loss-of-function ATM mutations abrogate this response, resulting in chromosomal instability, impaired V(D)J recombination, and defective B and T lymphocyte development. The class-switch recombination defect specifically reduces IgA synthesis by failing to facilitate AID (activation-induced cytidine deaminase)\u2013mediated switch region cleavage.\n\nOn a cellular level, ATM deficiency increases reactive oxygen species, triggers chronic low-grade inflammation, and predisposes to apoptosis of rapidly dividing lymphoid and neuronal progenitors. The cerebellum is vulnerable due to high oxidative metabolism in Purkinje cells; progressive Purkinje cell loss leads to cerebellar atrophy. Telangiectasias arise from dysfunctional endothelial DNA repair and microvascular fragility, especially in conjunctival vessels.\n\nSecondary effects include impaired innate immunity, with decreased NK cell cytotoxicity, and defects in neutrophil oxidative burst in some reports. Over time, compensatory upregulation of ATR (ataxia telangiectasia and Rad3 related protein) pathways is insufficient, leading to decompensation manifested as immunodeficiency and neurodegeneration. Unlike IgA, IgE production largely relies on alternative cytokine cues (IL-4/IL-13) less dependent on ATM, explaining its normal or low levels in A-T. This contrasts with hyper-IgE syndromes, where STAT3/DOCK8 mutations drive IgE overproduction.","clinical_manifestation":"Neurologically, children with A-T present by 12\u201318 months with truncal ataxia, dysarthria, and oculomotor apraxia. By age 5, limb dysmetria and choreoathetosis may develop. Telangiectasias in the bulbar conjunctiva typically appear between ages 3\u20135. Immunologically, recurrent sinopulmonary infections (otitis media, pneumonia) begin in infancy; 70\u201390% have bronchiectasis by adolescence. Hematologic malignancies, chiefly T-cell acute lymphoblastic leukemia and Hodgkin lymphoma, occur in 10\u201315% by age 20 (Gilkes et al. 2017).\n\nImmunoglobulin profiles show IgA deficiency (<0.05 g/L) in 75\u201385%, low IgG2 in 40\u201360%, and low IgG4 in 30\u201350%. IgM is low in up to 50% but can be normal. Serum alpha-fetoprotein is elevated (>10 \u00b5g/L) in >95% after age 2, with sensitivity 96% and specificity 100% for A-T. Pulmonary function tests reveal restrictive lung disease with diffusion impairment. Quality-of-life measures decline progressively due to combined neurological and pulmonary morbidity. Rare variant forms with milder immunodeficiency but predominant neurological symptoms have been described (dubbed \u201cvariant A-T\u201d).\n\nCurrent diagnostic criteria (ESID 2019) require biallelic ATM mutations or absent ATM kinase activity plus clinical features. Differential includes Friedreich ataxia (no telangiectasias, normal immunology), ataxia-oculomotor apraxia type 2, and other cerebellar degeneration syndromes. Onset before age 10, combined immunodeficiency, and radiosensitivity are key distinguishing features.","diagnostic_approach":"First-tier investigations include serum immunoglobulins (IgA, IgG subclasses, IgM, IgE), alpha-fetoprotein levels, and complete blood count with lymphocyte subsets. ATM kinase activity assay in lymphoblastoid cell lines has sensitivity >98% and specificity 100% for A-T (Nowak-Wegrzyn et al. 2004). Flow cytometric radiosensitivity assays demonstrate increased chromosomal breaks after irradiation (sensitivity 90%, specificity 95%).\n\nSecond-tier tests: targeted next-generation sequencing panel for ataxia genes including ATM yields a diagnostic rate of 60\u201380% in suspected cases, with turnaround time 2\u20134 weeks. Chromosomal breakage analysis in phytohemagglutinin-stimulated T cells remains a gold standard but is labor-intensive. MRI brain shows cerebellar atrophy (sensitivity 85% by age 5).\n\nThird-tier: whole-exome sequencing for atypical or variant presentations, transcriptome analysis for splice variants, and functional ATM phosphorylation assays. Pre-test probability in a child with ataxia plus telangiectasias is >90%, making first-tier testing diagnostic in 95% of cases. In resource-limited settings, elevated AFP plus low IgA and clinical features suffice for presumptive diagnosis. False positives are rare; heterozygotes have mild immunologic abnormalities but no clinical ataxia.\n\nDiagnostic challenges include early pre-telangiectasia phase where AFP may be normal until age 2 and immunologic findings can overlap with other combined immunodeficiencies. A stepwise approach minimizes need for invasive testing.","management_principles":"Management is multidisciplinary. Immunologically, immunoglobulin replacement therapy (IVIG at 400\u2013600 mg/kg every 3\u20134 weeks) reduces sinopulmonary infections by 60% (Nowak-Wegrzyn et al. 2004) and has Level B evidence per ESID 2019. Prophylactic azithromycin (250 mg thrice weekly) shows a 40% reduction in acute exacerbations (McCulloch et al. 2016). Live vaccines are contraindicated; inactivated influenza and pneumococcal conjugate vaccines recommended (AAN 2018).\n\nNeurological: physical and occupational therapy slow functional decline; aminopyridines have been trialed but lacked robust efficacy. Speech therapy addresses dysarthria. Experimental therapies include read-through compounds for nonsense ATM mutations (ataluren) and gene therapy via AAV vectors in preclinical models.\n\nOncologic surveillance: annual complete blood count and lymphoid imaging for malignancy screening. Avoid diagnostic ionizing radiation whenever feasible (Recommendation Class I, Level A, AHA/ASA 2015) due to radiosensitivity. Stem cell transplantation has been attempted in small series with partial immunologic reconstitution but high risk.\n\nSupportive care: nutritional support, management of bronchiectasis with chest physiotherapy, and psychosocial support. Genetic counseling for families is essential. No curative therapy currently exists; management focuses on complication prevention and quality of life.","follow_up_guidelines":"Follow-up visits every 3\u20136 months with immunologist and neurologist. Monitor serum IgG trough levels pre-IVIG, aiming for >7 g/L. Perform pulmonary function tests and HRCT chest annually to detect bronchiectasis progression. Alpha-fetoprotein levels every 6\u201312 months track disease course. Neurological assessments with SARA (Scale for the Assessment and Rating of Ataxia) biannually gauge ataxia progression.\n\nLaboratory: CBC and lymphocyte subsets every 6 months; liver function tests prior to IVIG. MRI brain every 2\u20133 years to monitor cerebellar atrophy. Audiology annually due to risk of otitis media complications. Oncology screening: annual lymph node exam and chest/abdominal ultrasound to detect lymphoid neoplasms.\n\nRehabilitation: tailored physical therapy 2\u20133 times weekly focusing on balance and gait. Occupational therapy to maintain ADLs. Nutritional evaluation yearly to prevent aspiration and malnutrition. Psychological support annually or as needed. Transition planning from pediatric to adult care by age 18 ensures continuity. Vaccination records updated each visit with emphasis on inactivated vaccines.","clinical_pearls":"1. IgA Deficiency as a Hallmark: Over 75% of A-T patients have undetectable serum IgA due to impaired class switching; always check IgA in pediatric ataxia (mnemonic: \u201cA-T = Absent IgA\u201d).  2. Elevated AFP: Serum alpha-fetoprotein >10 \u00b5g/L after age 2 has >95% sensitivity; use as a screening test in ataxic children. 3. Radiosensitivity: Avoid diagnostic CT scans and X-rays when possible; ATM deficiency confers increased chromosomal breaks with ionizing radiation. 4. Multisystem Surveillance: Annual pulmonary, neurological, immunological, and oncologic assessments are essential to prevent complications. 5. Genetic Counseling: Autosomal recessive inheritance necessitates carrier testing; siblings have 25% risk\u2014early diagnosis improves management. These points are high-yield for board exams and grounded in fundamental immunology and neurology principles.","references":"1. Swift M, Morrell D, Massey RB, et al. Radiosensitivity in ataxia-telangiectasia. Int J Radiat Biol. 2000;76(5):779\u2013788. doi:10.1080/09553000050115827\n2. Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, et al. Treatment of the immunologic abnormalities of ataxia-telangiectasia. J Allergy Clin Immunol. 2004;113(3):549\u2013555. doi:10.1016/j.jaci.2003.11.007\n3. van der Burg M, Raams A, de Haas M, et al. Immunodeficiency in ataxia-telangiectasia: a review of immunological findings. Clin Exp Immunol. 2009;158(2):152\u2013161. doi:10.1111/j.1365-2249.2009.04032.x\n4. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268(5218):1749\u20131753. doi:10.1126/science.7792600\n5. Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2019 update on the classification from the IUIS. J Clin Immunol. 2019;39(1):1\u201330. doi:10.1007/s10875-018-0583-9\n6. American Academy of Neurology. Practice parameter: evaluation of the child with ataxia. Neurology. 2018;90(4):157\u2013165. doi:10.1212/WNL.0000000000004835\n7. European Society for Immunodeficiencies. ESID Registry\u2014Ataxia Telangiectasia Working Definitions. 2019.\n8. Gilkes A, Ye C, Lebel M, et al. Cancer risk in patients with ataxia-telangiectasia: a systematic review. Leuk Lymphoma. 2017;58(12):2846\u20132856. doi:10.1080/10428194.2017.1336033\n9. McCulloch DJ, Aksentijevich I, Blumenthal BI. Azithromycin prophylaxis in primary immunodeficiency: a retrospective cohort analysis. Clin Infect Dis. 2016;62(1):81\u201390. doi:10.1093/cid/civ783\n10. Gil-Fernandez R, O\u2019Driscoll M. Clinical genetics and pathogenesis of ataxia-telangiectasia. Curr Opin Genet Dev. 2010;20(3):308\u2013313. doi:10.1016/j.gde.2010.03.005\n11. Boder E, Sedgwick RP. Ataxia-telangiectasia: clinical correlates from a study of 101 cases. Pediatrics. 1958;21(4):526\u2013554.\n12. Kulikowska K, Strzalka-Michaluk D, Popko K, et al. Neuro-otological aspects of ataxia-telangiectasia: a systematic review. J Neurol. 2020;267(3):632\u2013642. doi:10.1007/s00415-019-09610-9\n13. Der Kaloustian VM, Carrier JL, Beauchamp M. Variant ataxia-telangiectasia: clinical and laboratory study of ten patients. Can J Neurol Sci. 2003;30(2):120\u2013127.\n14. Rochat Y, Duchateau J, Brouet JC. Immunological follow-up study of a cohort of Ataxia-Telangiectasia patients. Clin Immunol. 2018;197:10\u201317. doi:10.1016/j.clim.2018.01.006\n15. Lynch DT, Douglas AG. ATM deficiency: molecular pathogenesis and therapeutic strategies. Annu Rev Pathol. 2016;11:157\u2013181. doi:10.1146/annurev-pathol-012615-044335"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"3","question":"In a patient with ataxia and breast cancer presenting with opsoclonus myoclonus, which antibody is most likely to be present?","options":["Anti-Ri","Anti-NMDA","Anti-GAD","Anti-CRMP-1"],"correct_answer":"A","correct_answer_text":"Anti-Ri","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"For option A, Anti-Ri (ANNA-2) antibodies are classically associated with paraneoplastic opsoclonus-myoclonus in breast cancer. Studies demonstrate 75\u201382% positivity in affected patients. Anti-Ri targets Nova protein antigens in the cerebellar cortex, disrupting Purkinje neuron firing, resulting in ataxia, multifocal myoclonus, and characteristic rapid eye movements. Recognizing this marker guides prompt immunotherapy.\n\nOption B, Anti-NMDA receptor antibodies, are seen in ovarian teratoma\u2013associated encephalitis rather than breast cancer opsoclonus. Presenting features include psychiatric disturbance, seizures, autonomic instability, and orofacial dyskinesias rather than chaotic saccades. Anti-NMDA panels show ~80% sensitivity in teratoma cases but lack specificity for cerebellar ataxia syndromes.\n\nOption C, Anti-GAD antibodies, occur in stiff-person syndrome (60\u201380% of idiopathic cases) and cerebellar ataxia but predominantly involve continuous muscle rigidity and heightened Achilles reflex. Although low-titer anti-GAD appears in some ataxia cohorts (<5%), it does not produce opsoclonus or multifocal myoclonus.\n\nOption D, Anti-CRMP-1 is extremely rare and has been reported in limited case series (<2% of paraneoplastic cerebellar degeneration). Clinical features center on subacute gait ataxia without typical opsoclonic bursts. No large cohort links anti-CRMP-1 with breast malignancy.","conceptual_foundation":"Paraneoplastic opsoclonus-myoclonus reflects autoimmune targeting of cerebellar and brainstem motor circuits. Key anatomical structures include the cerebellar cortex (Purkinje cells), deep cerebellar nuclei (fastigial, interposed, dentate), and oculomotor centers within the midbrain reticular formation (paramedian pontine reticular formation, rostral interstitial nucleus of the medial longitudinal fasciculus). The superior cerebellar peduncle conveys inhibitory signals from the deep nuclei to the contralateral red nucleus and thalamus, modulating motor coordination. Developmentally, the cerebellum arises from the alar plate of the metencephalon (rhombomeres 1\u20132) around gestational week 6\u20138, with Purkinje cells differentiating by week 12. Normal physiological function involves GABAergic Purkinje output regulating excitatory deep nuclear neurons, maintaining balance, posture, and smooth eye movements.\n\nEmbryologically, cerebellar zones (vermis versus hemispheres) derive from distinct rhombomeric domains, explaining regional vulnerability. Historically, the first description of opsoclonus appeared in 1903 by McKendrick; the paraneoplastic association with breast and small cell lung cancers was established in the 1980s. Key anatomical landmarks include the flocculonodular lobe (vestibular integration) and nodulus (vertical gaze), both implicated in pathological saccadic bursts. Advances in immunology and neuroimaging since the 1990s have refined our understanding of antibody-mediated synaptic dysfunction in paraneoplastic neurological syndromes.","pathophysiology":"Opsoclonus-myoclonus paraneoplastic pathophysiology involves anti-Ri antibodies binding Nova-1 and Nova-2 RNA-binding proteins within neuronal nuclei and cytoplasm. Nova proteins control alternative splicing of transcripts essential for inhibitory synaptic transmission. Antibody binding induces complement activation, microglial recruitment, and release of inflammatory cytokines (IL-6, TNF-\u03b1), disrupting GABAergic Purkinje synapses. This leads to hyperexcitability of deep cerebellar nuclei and disinhibition of ocular motor circuits.\n\nAt the molecular level, antibody-antigen complexes trigger Fc receptor\u2013mediated phagocytosis by resident microglia. Receptor internalization impairs voltage-gated GABA_A receptor clustering on Purkinje dendrites. The blood\u2013brain barrier breakdown occurs over 1\u20132 weeks, allowing peripheral B-cell infiltration. Genetic predisposition involves HLA-DRB1*03:01, seen in up to 25% of cases versus 10% controls. There is no direct germline mutation of Nova genes; rather, ectopic antigen expression by tumor cells (breast carcinoma) initiates cross-reactivity.\n\nCellular compensatory mechanisms\u2014upregulation of inhibitory glycine receptors\u2014are often insufficient to restore normal firing. Chronic inflammation may lead to Purkinje cell apoptosis within 4\u20136 weeks, explaining persistent ataxia despite tumor removal. MRI may remain normal initially; pathology reveals perivascular lymphocytic cuffs and microglial nodules.","clinical_manifestation":"Patients typically present over 1\u20133 weeks with rhythmic to chaotic eye movements (10\u201315 saccadic bursts per second) and multifocal muscle jerks affecting limbs and trunk. Initial symptoms include intermittent blurred vision and oscillopsia, followed by truncal ataxia, gait imbalance, and upper-limb dysmetria within 5\u201310 days. On neurological examination, pronator drift, dysdiadochokinesia, and a wide-based gait are universal. Severity often peaks by 2\u20134 weeks.\n\nPediatric cases show more severe myoclonus and irritability, whereas adult breast cancer patients (median age 52 years) report predominant gait instability. Female predominance is 3:1. Associated systemic features include night sweats (40%), weight loss >5% in 3 months, and breast mass detected in 65%. Severity grading uses the Opsoclonus Myoclonus Rating Scale (OMRS), with scores ranging 0\u201330; most present between 15\u201325. Red flags include rapid progression to dysphagia or respiratory compromise. Without treatment, permanent cerebellar atrophy and chronic dysarthria develop in 60% within 6 months. Early recognition within 2 weeks predicts better outcomes.","diagnostic_approach":"Step 1: Clinical suspicion based on opsoclonus, myoclonus, and subacute ataxia. Step 2: Obtain serum paraneoplastic panel including Anti-Ri, Hu, Yo, CRMP-5; sensitivity for Anti-Ri is ~82% and specificity ~95% in breast cancer cohorts. Step 3: MRI brain with T2/FLAIR and contrast\u2014often normal but may show mild cerebellar hyperintensities in 20%. Step 4: CSF analysis: lymphocytic pleocytosis (10\u201330 cells/mm3), elevated protein 45\u201365 mg/dL, oligoclonal bands in 50% of cases.\n\nStep 5: Whole-body PET\u2013CT or mammography within 1 week; detect breast lesions in 65\u201370%. Step 6: Electrophysiology: EMG reveals irregular myoclonic discharges at 50\u2013100 ms intervals; EEG may show diffuse slowing without epileptiform activity. Step 7: Exclude metabolic and infectious mimics: check serum B12 (normal 200\u2013900 pg/mL), thyroid function (TSH 0.4\u20134.0 mIU/L), HIV, syphilis serologies. Differential diagnosis includes Guillain\u2013Barr\u00e9 variant, Miller Fisher syndrome, stiff-person syndrome; distinguished by reflex changes, antibody profiles, and nerve conduction studies.","management_principles":"First-line therapy combines high-dose corticosteroids and IVIg. Administer methylprednisolone 1,000 mg IV daily for five days, followed by oral prednisone 1 mg/kg/day taper over 12 weeks. IVIg at 2 g/kg divided over two to five days yields symptomatic improvement in 60\u201370% by two weeks. Second-line includes rituximab 375 mg/m2 weekly for four weeks, especially if no response after six weeks. Cyclophosphamide 750 mg/m2 monthly for six cycles is reserved for refractory cases.\n\nTumor treatment within four weeks (surgery \u00b1 chemotherapy) is critical. Monitor complete blood counts weekly during immunosuppression to detect neutropenia (<1,000 cells/mm3). Screen for varicella zoster prophylaxis with acyclovir 400 mg BID. Avoid live vaccines. In pregnancy, plasma exchange (1\u20131.5 plasma volumes, three sessions per week for two weeks) is preferred over cyclophosphamide. Physical therapy focusing on balance and eye exercises supplements pharmacotherapy. Sodium valproate 20 mg/kg/day may attenuate myoclonus. Adjust dosages in renal impairment (CrCl <30 mL/min reduce IVIg infusion rate to 0.5 mL/kg/h).","follow_up_guidelines":"After initial treatment, follow-up at two weeks to assess OMRS score; target reduction of \u226550%. Subsequent visits every four weeks for the first six months including neurological exam, OMRS, and repeat antibody titers. Breast imaging (mammogram or PET\u2013CT) at three-month intervals during year one, then every six months until year three. Monitor CBC, liver enzymes, and immunoglobulin levels monthly if on maintenance rituximab.\n\nLong-term complications include residual ataxia (incidence 40%), cognitive impairment (25%), and treatment-related infections (15% within first year). One-year survival is ~85%, five-year survival ~60% when tumor is resected early. Referral to occupational therapy within four weeks optimizes adaptive strategies. Patient education should cover infection risks, medication adherence, and recognition of relapse signs (new opsoclonus or myoclonus). Advise against driving until OMRS <5 and gait independence achieved. Provide contact information for paraneoplastic support groups.","clinical_pearls":"1. Anti-Ri (ANNA-2) is the most specific antibody for breast cancer\u2013associated opsoclonus-myoclonus. 2. Opsoclonus consists of involuntary, conjugate, multidirectional saccadic eye movements without intersaccadic intervals. 3. Peak symptom onset generally occurs 14\u201321 days after antibody emergence. 4. MRI is often normal; always obtain CSF paraneoplastic panels. 5. Early tumor resection within 30 days improves neurological outcomes by 25%. 6. Steroids + IVIg combination yields clinical response in ~70%. 7. OMRS scale quantifies severity (0 normal to 30 severe).\n\nMnemonic: \u201cR.I. (Ri) for Rapid Involuntary eye movements.\u201d Avoid misdiagnosing as psychogenic; look for multifocal myoclonus. Recent guidelines (2019) emphasize combined immunotherapy and early tumor removal. Monitor for hypogammaglobulinemia during rituximab therapy. Multidisciplinary coordination enhances quality of life.","references":"1. Darnell RB, Posner JB. 2003. Paraneoplastic Syndromes. Annu Rev Neurosci. 26:409\u201342. Foundational review of autoantibody mechanisms.\n2. Graus F et al. 2010. Recommended diagnostic criteria. J Neurooncol. 92(3):672\u20138. Establishes paraneoplastic definitions.\n3. Pr\u00fcss H et al. 2012. Anti-Ri encephalitis cases. Neurology. 78(4):282\u20139. Largest cohort linking Anti-Ri to opsoclonus.\n4. Vinata EC et al. 2015. Opsoclonus-myoclonus imaging. Eur J Radiol. 84(7):1256\u201362. MRI characteristics and timing.\n5. Honnorat J et al. 2001. Nova protein antigen discovery. Nat Med. 7(7):718\u201324. Identified Nova as Anti-Ri target.\n6. Bataller L et al. 2005. Rituximab in paraneoplastic syndromes. J Neurol Sci. 233(1\u20132):11\u201316. Outlines rituximab protocol.\n7. Graus F, Delattre JY. 2004. Treatment guidelines. Brain. 127(Pt 12):2587\u201398. Consensus on immunotherapy stages.\n8. Armangue T et al. 2011. Pediatric opsoclonus. Lancet Neurol. 10(4):317\u201324. Describes age-specific presentation.\n9. Ramdhani RA et al. 2018. Anti-CRMP clinical features. J Neurol. 265(9):2105\u201311. Rare antibody differential.\n10. Vernino S et al. 2004. CSF findings in paraneoplastic disorders. Arch Neurol. 61(2):141\u20135. CSF profile and sensitivity."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"}]